About: Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study
Creator	Kim, Won-Young Choi, Jae Jung, Sun-Young You, Seung-Hun
Source	Medline; PMC
abstract	BACKGROUND: Renin-angiotensin-aldosterone system (RAAS) inhibitors may facilitate host cell entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or attenuate organ injury via RAAS blockade. We aimed to assess the associations between prior use of RAAS inhibitors and clinical outcomes among Korean patients with coronavirus 2019 (COVID-19). METHODS: We performed a nationwide population-based cohort study using the Korean Health Insurance Review and Assessment database. Claim records were screened for 66793 individuals who were tested for COVID-19 until April 8, 2020. Adjusted odds ratios (ORs) were used to compare the clinical outcomes between RAAS inhibitor users and nonusers. RESULTS: Among 5179 confirmed COVID-19 cases, 762 patients were RAAS inhibitor users and 4417 patients were nonusers. Relative to nonusers, RAAS inhibitor users were more likely to be older, male, and have comorbidities. Among 1954 hospitalized patients with COVID-19, 377 patients were RAAS inhibitor users and 1577 patients were nonusers. In-hospital mortality was observed for 33 RAAS inhibitor users (9%) and 51 nonusers (3%) (p<0.001). However, after adjustment for age, sex, Charlson Comorbidity Index, immunosuppression, and hospital type, the use of RAAS inhibitors was not associated with a higher risk of mortality (adjusted OR, 0.88; 95% confidence interval, 0.53–1.44; p=0.60). No significant differences were observed between RAAS inhibitor users and nonusers in terms of vasopressor use, modes of ventilation, extracorporeal membrane oxygenation, renal replacement therapy, and acute cardiac events. CONCLUSIONS: Our findings suggest that prior use of RAAS inhibitors was not independently associated with mortality among COVID-19 patients in Korea.
has issue date	2020-05-22(xsd:dateTime)
bibo:doi	10.1093/cid/ciaa624
bibo:pmid	32442285
has license	cc-by-nc-nd
sha1sum (hex)	83cec622d480f0475cdf40565dcc7954f0b8c9b7
schema:url	https://doi.org/10.1093/cid/ciaa624
resource representing a document's title	Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study
has PubMed Central identifier	PMC7314113
has PubMed identifier	32442285
schema:publication	Clin Infect Dis
resource representing a document's body	covid:83cec622d480f0475cdf40565dcc7954f0b8c9b7#body_text
is schema:about of	named entity 'COVID-19' named entity 'users' named entity 'inhibitor' named entity 'Association' named entity 'HAVE' named entity 'RAAS' named entity 'RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM' named entity 'INHIBITORS' named entity 'KOREA' named entity 'However' named entity 'RAAS' named entity 'RAAS' named entity 'cohort study' named entity 'higher risk' named entity 'mortality rate' named entity 'cohort study' named entity 'COVID' named entity 'hydroxychloroquine' named entity 'oxygen therapy' named entity 'ACE2' named entity 'SAS software' named entity 'host cell' named entity 'vasopressor' named entity 'SARS-CoV-1' named entity 'nasopharyngeal swab' named entity 'medical specialties' named entity 'East Asian' named entity 'COVID' named entity 'COVID -19' named entity 'acute heart failure' named entity 'ACE2' named entity 'angiotensin receptor blockers' named entity 'angiotensin II' named entity 'lung' named entity 'mortality rate' named entity 'methylprednisolone' named entity 'ACE2' named entity 'COVID-19' named entity 'RAAS' named entity 'chronic kidney disease' named entity 'diabetes' named entity 'hypercholesterolemia' named entity 'RAAS' named entity 'organ' named entity 'lung' named entity 'diabetes' named entity 'angiotensin II' named entity 'coronavirus infection' named entity 'myocardial infarction' named entity 'cardiovascular diseases' named entity 'dopamine' named entity 'ACE2' named entity 'RAAS' named entity 'cardiac events' named entity 'heart failure' named entity 'COVID' named entity 'intravenous' named entity 'RAAS' named entity 'ventilatory support' named entity 'HIRA' named entity 'U07.1' named entity 'Chung-Ang University' named entity 'hypertension' named entity 'HIRA' named entity 'SARS-CoV-2' named entity 'lung' named entity 'ACE2' named entity 'COVID' named entity 'norepinephrine' named entity 'COVID' named entity 'Hubei province, China' named entity 'older age' named entity 'intravenous' named entity 'hypertension' named entity 'peer-reviewed' named entity 'RAAS' named entity 'COVID' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software